Concert Pharmaceuticals Inc. (NASDAQ:CNCE) traded down 0% during trading on Friday . The company traded as low as $11.56 and last traded at $11.79, with a volume of 51,884 shares changing hands. The stock had previously closed at $11.79.

A number of equities research analysts have recently commented on the stock. Brean Capital reiterated a “buy” rating on shares of Concert Pharmaceuticals in a report on Saturday, April 30th. Stifel Nicolaus assumed coverage on shares of Concert Pharmaceuticals in a report on Friday, July 1st. They set a “buy” rating and a $23.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday, May 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.43.

The firm has a 50-day moving average of $12.15 and a 200-day moving average of $13.78. The firm has a market cap of $262.15 million and a price-to-earnings ratio of 14.17.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.18. Analysts predict that Concert Pharmaceuticals Inc. will post ($2.57) EPS for the current fiscal year.

In other Concert Pharmaceuticals news, CEO Roger D. Tung purchased 19,610 shares of Concert Pharmaceuticals stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average price of $10.55 per share, for a total transaction of $206,885.50. Following the acquisition, the chief executive officer now owns 538,965 shares in the company, valued at approximately $5,686,080.75. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

An institutional investor recently raised its position in Concert Pharmaceuticals stock. California Public Employees Retirement System boosted its stake in Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 22.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 103,700 shares of the company’s stock after buying an additional 18,700 shares during the period. California Public Employees Retirement System owned about 0.47% of Concert Pharmaceuticals worth $1,967,000 as of its most recent filing with the SEC.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.